The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.
Presented at AAO 2023, Kendra Klein-Mascia, MD, discussed her team’s study, comparing faricimab with aflibercept. The study found 2 injections of faricimab gets rid of 75% of retina fluid by week 8, but for aflibercept, erasing the same amount of fluid takes 3 injections until week 12.
Presented at AAO 2023, a study analyzed which race was associated more with having a glaucoma-associated diagnosis, as well as races’ knowledge, attitude, and beliefs about eye care.
Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.
Data presented at ASN Kidney Week 2023 highlighted the patient-reported difficulty of implementing physician-recommended lifestyle changes but noted significant impacts on physical health, mental health, and overall quality of life when done successfully.
Richard Johnson, MD, discusses the results of a study from ASN Kidney Week 2023 detailing the effects of urate-lowering therapy on blood pressure among patients with gout.
Two studies presented at AAO demonstrate that low dose atropine is associated with slowing myopia progression, but another study finds that this is not true. Thus, there are mixed results on this relationship.